BCI

The Breast Cancer Index (BCI) test helps determine the benefit of extended endocrine therapy and the risk of late recurrence in hormone receptor-positive (HR+), early-stage breast cancer.

BCI – Breast Cancer Index for Extended Endocrine Therapy Decision-Making

Personalized guidance for hormone therapy in early-stage breast cancer.

icon

Predicts Benefit of Extended Therapy: Identifies patients likely to benefit from endocrine therapy beyond 5 years

icon

Assesses Late Recurrence Risk: Evaluates likelihood of cancer returning after initial treatment window

icon

Personalized Care: Supports tailored treatment planning based on tumor biology

icon

Non-Invasive: Performed on archived tumor tissue

icon

Clinically Proven: Validated in multiple studies; recommended by ASCO and NCCN guidelines

What is the Breast Cancer Index (BCI) Test?

BCI analyzes the expression of seven genes associated with estrogen signaling and tumor proliferation.
It provides two results: the H/I ratio (predictive of endocrine therapy benefit) and a risk score for late recurrence (years 5–10).

Important To Know
Test Name: Breast Cancer Index (BCI) Performing Laboratory: Biotheranostics, a Hologic Company Sample Type: FFPE breast tumor tissue Turnaround Time: 7–10 business days Contact Information: Phone: 03-5541464 Email: contact@progenetics.co.il Company: Progenetics – Advancing Personalized Medicine

The Testing Process

01
Tissue Sample Retrieval

Archived tumor sample (from biopsy or surgery) is sent to the lab

02
Gene Expression Profiling

Seven key genes are analyzed for expression levels

03
Dual Results Provided

Risk of late recurrence and likelihood of benefit from extended therapy

04
Shared Decision-Making

Results guide discussion between patient and physician

Who Should Consider the Test?

icon

Women with early-stage, HR-positive, node-negative or node-positive breast cancer

icon

Patients who have completed 4–5 years of endocrine therapy and are considering continuation

icon

Physicians aiming to reduce unnecessary treatment and optimize outcomes

Clinical and scientific information

Technology
  • Technology: Reverse transcription PCR (RT-PCR) gene expression assay
  • Validation: Demonstrated clinical utility in studies including ATAC and MA.17
  • Guideline Recognition: Included in ASCO and NCCN guidelines for endocrine therapy decision-making
  • Technology: Reverse transcription PCR (RT-PCR) gene expression assay
  • Validation: Demonstrated clinical utility in studies including ATAC and MA.17
  • Guideline Recognition: Included in ASCO and NCCN guidelines for endocrine therapy decision-making

FAQ

No. BCI is specifically focused on predicting late recurrence and extended therapy benefit, often used after initial treatment.

BCI is covered by Medicare and many private insurers. Contact us for eligibility assistance.

A preserved tumor tissue sample from a prior biopsy or surgery.